T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition
Retrieved on:
Monday, September 27, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, THAC, Patent, Infection, EADS, University, Peripheral neuropathy, Public sector, Roy Taylor (scientist), French Government of the Hundred Days, COVID-19, Pandemic, Ageing, Dysbiosis, Patient, ADA, Louis Pasteur, Lists of diseases, CSIS, INRA, Diabetes, Disease, CEO, Industry, Acquisition, University of Paris, Company, Growth, Microbiota, University of South Florida, Science, Global Virus Network, Human, Travancore–Cochin, Research, Obesity, Insulin, Hospital, Â, Sanofi, Insulin resistance, R, SA, Doctor of Philosophy, INSERM, Degenerative disease, Pharmaceutical industry, Management
This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.
Key Points:
- This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota.
- It allows to reinforce our robust patent portfolio as well as to develop a competitive oral formulation for our product.
- With this patent, we accelerate our development, and we strengthen our competitive position on the market.
- The dysbiosis, disequilibrium of the gut flora in humans, is characterized by complex changes in the microbiota and its various micro-organisms.